$PMN News
Last published 6d ago
- 6d agoPMNProMIS Neurosciences to Participate in Upcoming Conferences in NovemberGlobeNewswireCAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in
- 1w agoPMNProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026GlobeNewswireCambridge, Massachusetts, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded
- 2mo agoPMNProMIS Neurosciences to Participate in Upcoming Conferences and Events in SeptemberGlobeNewswireCAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in
- 3mo agoPMNProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate HighlightsGlobeNewswireAnnounced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases of
- 3mo agoPMNProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026GlobeNewswireCompany to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company
- 3mo agoPMNProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease TrialGlobeNewswireNo ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline results expected in Q1 2027
- 3mo agoPMNProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s DiseaseGlobeNewswireCambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded
- 4mo agoPMNProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026GlobeNewswirePMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers Represents one of the first quantitative measures of
- 5mo agoPMNProMIS Neurosciences to Participate in Upcoming Conferences in JuneGlobeNewswireCAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in
- 6mo agoPMNProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate HighlightsGlobeNewswireCompany closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through 2027, including
- 7mo agoPMNProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate HighlightsGlobeNewswirePRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310
- 9mo agoPMNProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireCambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other
- 9mo agoPMNProMIS Neurosciences Announces Up to $175 Million Private Placement FinancingGlobeNewswireExtends cash runway into 2028 Proceeds expected to enable completion of ProMIS' landmark Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected mid-2026;
- 10mo agoPMNProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's DiseaseGlobeNewswireLarge, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer's disease Clear and near-term value inflection points, with blinded 6-month interim data
- 11mo agoPMNProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA RiskGlobeNewswireResults support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer's
- 11mo agoPMNProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310GlobeNewswireCross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS' PRECISE-AD trial ProMIS on track to leverage new plasma pTau insights
- 11mo agoPMNProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswireCambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other
- 11mo agoPMNProMIS Neurosciences Announces Reverse Stock SplitGlobeNewswireCambridge, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other
- 12mo agoPMNProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate HighlightsGlobeNewswirePhase 1b trial in Alzheimer's disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolledPMN310 continues to demonstrate a favorable safety profileOn track to report 6-month interim data in Q2 2026 and final
- 1y agoPMNProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation ConferenceGlobeNewswireCambridge, Massachusetts, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other
- 1y agoPMNProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge GroupGlobeNewswireAppointment reinforces ProMIS Neurosciences' strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer's program, PMN310 Cambridge, Massachusetts, Oct. 22, 2025 (GLOBE
- 1y agoPMNProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310GlobeNewswireCohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 128 patients,
- 1y agoPMNProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate HighlightsGlobeNewswireU.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer's Disease, enhancing program's potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer's Disease Progressing on Schedule: Over 50% enrolled,
- 1y agoPMNProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International ConferenceGlobeNewswirePresentation to highlight the Company's proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company's Phase 1b clinical trial design and optimization of
- 1y agoPMNProMIS Neurosciences Announces Private Placement FinancingGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Massachusetts, July 28, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic
- 1y agoPMNProMIS Neurosciences Announces Private Placement FinancingGlobeNewswireTORONTO, Ontario and CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic
- 1y agoPMNProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq RulesGlobeNewswireCAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting
- 1y agoPMNProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's DiseaseGlobeNewswireCAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies targeting toxic
- 1y agoPMNProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceGlobeNewswireCAMBRIDGE, Massachusetts, June 17, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective
- 1y agoPMNProMIS Neurosciences Announces First Quarter 2025 Financial ResultsGlobeNewswireFirst Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts,
- 1y agoPMNProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent HighlightsGlobeNewswireRapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer's Disease PRECISE-AD Six Month Interim Results Expected in 1H 2026 with
- 1y agoPMNProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International ConferenceGlobeNewswireCAMBRIDGE, Massachusetts, March 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and
- 1y agoPMNProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual MeetingGlobeNewswireCAMBRIDGE, Massachusetts , March 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and
- 1y agoPMNProMIS Neurosciences to Participate in the 37th Annual Roth ConferenceGlobeNewswireCAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting
- 1y agoPMNProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's DiseaseGlobeNewswireRapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer's Disease Six-month Interim Results Expected in 1H 2026 with Topline Results
- 1y agoPMNProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceGlobeNewswireCAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting
- 1y agoPMNProMIS Neurosciences Issues Letter to ShareholdersGlobeNewswireCAMBRIDGE, Massachusetts, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics
- 1y agoPMNProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's DiseaseGlobeNewswireCAMBRIDGE, Massachusetts, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today
- 1y agoPMNProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx ConferenceGlobeNewswireCAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody
- 1y agoPMNProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent HighlightsGlobeNewswirePresented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential target engagement
- 1y agoPMNProMIS Neurosciences to Participate in Guggenheim's Inaugural Healthcare Innovation ConferenceGlobeNewswireCAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody
- 2y agoPMNProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease ConferenceGlobeNewswireResults indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of Phase 1b clinical trial in Alzheimer's disease patients planned for
- 2y agoPMNProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral NeurosciencesGlobeNewswireCAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics
- 2y agoPMNProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireCAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 05, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting
- 2y agoPMNProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent HighlightsGlobeNewswireReported positive topline data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease that met objectives for tolerability, safety and pharmacokinetics Secured up to $122.7 million
- 2y agoPMNProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open BiologyGlobeNewswireBody of work supports targeting misfolded proteins as a therapeutic strategy for ALS with the potential to translate across multiple neurodegenerative diseases CAMBRIDGE, Massachusetts and TORONTO, Ontario , Aug. 06,
- 2y agoPMNProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024GlobeNewswireCAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic
- 2y agoPMNProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International ConferenceGlobeNewswirePreclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for potential Alzheimer's disease vaccine CAMBRIDGE, Massachusetts and
- 2y agoPMNProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's TrialGlobeNewswireTopline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive
- 2y agoPMNProMIS Neurosciences Announces Up to $122.7 Million Private Placement FinancingGlobeNewswire$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approval Fundraise supports development of novel antibody PMN310